Cellectis (CLLS) Change in Receivables (2015 - 2026)
Cellectis (CLLS) recorded quarterly Change in Receivables of $7.9 million in Q1 2026, up 116.45% quarter-over-quarter from $3.7 million in Q3 2025, and up 3550.0% on a YoY basis from $217397.3 in Q1 2025.
Cellectis (CLLS) Change in Receivables (2015 - 2026) Analysis & Trends
Cellectis' Change in Receivables history runs 12 years deep, the most recent figure standing at $7.9 million for Q1 2026.
- In Q1 2026, Change in Receivables rose 3550.0% year-over-year to $7.9 million; the TTM figure through Mar 2026 stood at $9.5 million (down 85.59% YoY), while the FY2024 annual figure was $52.6 million, up 2235.52% from the prior year.
- Change in Receivables was $7.9 million for Q1 2026 at Cellectis, up from $3.7 million in the prior quarter.
- In the past five years, Change in Receivables ranged from a high of $61.4 million in Q2 2024 to a low of -$13.5 million in Q1 2024.
- Historically, Change in Receivables has averaged $3.8 million across 5 years, with a median of $171500.0 in 2022.
- The sharpest annual moves came in 2023 and 2026: Change in Receivables slumped 3769.7% in 2023, then soared 3550.0% in 2026.
- A 5-year view of Change in Receivables shows it stood at $578000.0 in 2022, then soared by 203.29% to $1.8 million in 2023, then surged by 144.78% to $4.3 million in 2024, then slipped by 14.57% to $3.7 million in 2025, then soared by 116.45% to $7.9 million in 2026.
- The last three Change in Receivables figures came in at $7.9 million (Q1 2026), $3.7 million (Q3 2025), and -$1.9 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 22,529.00 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | -39.80 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -4.08 Mn |
| 10 | Cellectis | 17.40 Bn | 17.21 Bn | - | 7.94 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 7.94 Mn |
| Mar 31, 2026 | 7.94 Mn |
| Sep 30, 2025 | 3.67 Mn |
| Sep 30, 2025 | 3.67 Mn |
| Jun 30, 2025 | -1.88 Mn |
| Jun 30, 2025 | -1.88 Mn |
| Mar 31, 2025 | -230,000.00 |
| Mar 31, 2025 | -230,000.00 |
| Dec 31, 2024 | 4.29 Mn |
| Dec 31, 2024 | 4.29 Mn |
| Sep 30, 2024 | 376,000.00 |
| Sep 30, 2024 | 376,000.00 |
| Jun 30, 2024 | 61.39 Mn |
| Jun 30, 2024 | 61.39 Mn |
| Mar 31, 2024 | -13.46 Mn |
| Mar 31, 2024 | -13.46 Mn |
| Dec 31, 2023 | 1.75 Mn |
| Dec 31, 2023 | 1.75 Mn |
| Sep 30, 2023 | -497,000.00 |
| Sep 30, 2023 | -497,000.00 |